Research.Patient.info

Early triple-negative breast cancer (TNBC) research hub

1 indexed studies · 0 currently recruiting

authorisedTherapeutic exploratory (Phase II)
SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK
This study is looking at a new treatment called INT230-6, given as an injection directly into breast tumours, alongside standard chemotherapy and immunotherapy for early triple-negative breast cancer. It aims to see how well it shrinks tumours before surgery.
France